Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential

Deregulated activity of the Src tyrosine kinases leads to malignant transformation. Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera-Torres, José, San José, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759511/
https://www.ncbi.nlm.nih.gov/pubmed/31619990
http://dx.doi.org/10.3389/fphar.2019.01011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759511/
https://www.ncbi.nlm.nih.gov/pubmed/31619990
http://dx.doi.org/10.3389/fphar.2019.01011

Ejemplares similares